CPPG
CPPG structure
|
Common Name | CPPG | ||
|---|---|---|---|---|
| CAS Number | 183364-82-1 | Molecular Weight | 271.20600 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C11H14NO5P | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of CPPGCPPG ((RS)-CPPG) is a potent group II/III mGlu receptor antagonist. CPPG exhibits some selectivity (approximately 20 fold) for group III (IC50=2.2 nM) over group II (IC50=46.2 nM) mGlu receptors in the rat cerebral cortex. CPPG has weak effects at group I mGlu receptors[1]. |
| Name | CPPG,(RS)-α-Cyclopropyl-4-phosphonophenylglycine |
|---|---|
| Synonym | More Synonyms |
| Description | CPPG ((RS)-CPPG) is a potent group II/III mGlu receptor antagonist. CPPG exhibits some selectivity (approximately 20 fold) for group III (IC50=2.2 nM) over group II (IC50=46.2 nM) mGlu receptors in the rat cerebral cortex. CPPG has weak effects at group I mGlu receptors[1]. |
|---|---|
| Related Catalog | |
| In Vitro | CPPG ((RS)-CPPG) potently reversed both L-AP4 (IC50=2.2 nM)- and L-CCG-I (IC50=46.2 nM) -mediated inhibition of forskolin-stimulated cyclic AMP accumulation in adult rat cortical slices. CPPG is a potent antagonist against group II/III mGlu receptors in the adult rat cortex and shows moderate selectivity for group III mGlu receptors. Conversely, CPPG has weak effects at group I mGlu receptors in both the neonatal rat cortex and cultured cerebellar granule cells[1]. |
| References |
| Molecular Formula | C11H14NO5P |
|---|---|
| Molecular Weight | 271.20600 |
| Exact Mass | 271.06100 |
| PSA | 130.66000 |
| LogP | 0.83850 |
|
Examination of VLC-PUFA-deficient photoreceptor terminals.
Invest. Ophthalmol. Vis. Sci. 55(7) , 4063-72, (2014) Juvenile-onset autosomal dominant Stargardt-like macular dystrophy (STGD3) is caused by mutations in ELOVL4 (elongation of very long fatty acids-4), an elongase necessary for the biosynthesis of very ... |
|
|
Neuroprotective potential of the group III mGlu receptor agonist ACPT-I in animal models of ischemic stroke: In vitro and in vivo studies.
Neuropharmacology 102 , 276-94, (2016) In the present study, we investigated the effect of ACPT-I [(1S, 3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid], a blood-brain-barrier permeable agonist of group III mGlu receptor, against oxyge... |
|
|
Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action.
Neuropharmacology 85 , 166-77, (2014) Metabotropic glutamate 4 (mGlu4) receptor is a promising target for the treatment of motor deficits in Parkinson's disease (PD). This is due in part to its localization at key basal ganglia (BG) synap... |
| CPPG |
| Water,sterile filtered |